×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AMRN – amarin corporation plc - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AMRN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/2
08:00 am
amrn
Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology
Low
Report
Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology
2/25
02:36 pm
amrn
Amarin Corp PLC (AMRN) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines with ... [Yahoo! Finance]
Medium
Report
Amarin Corp PLC (AMRN) Q4 2025 Earnings Call Highlights: Navigating Revenue Declines with ... [Yahoo! Finance]
2/25
11:27 am
amrn
Amarin Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Amarin Q4 Earnings Call Highlights [Yahoo! Finance]
2/25
10:51 am
amrn
Amarin (AMRN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Amarin (AMRN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
2/25
07:18 am
amrn
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
High
Report
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
2/25
07:00 am
amrn
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
2/23
08:00 am
amrn
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
Low
Report
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
2/11
08:00 am
amrn
Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
Low
Report
Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
Date
Time
Symbol
Company Name
Action
%Chg
10/29/2025
07:00 am
AMRN
amarin corporation plc - american depositary shares
BEAT
Report
-14.8%
amarin corporation plc - american depositary shares
7/30/2025
07:00 am
AMRN
amarin corporation plc - american depositary shares
BEAT
Report
3.2%
amarin corporation plc - american depositary shares
3/12/2025
07:00 am
AMRN
amarin corporation plc - american depositary shares
BEAT
Report
-12.8%
amarin corporation plc - american depositary shares
3/12/2025
07:00 am
AMRN
amarin corporation plc - american depositary shares
BEAT
Report
-9.0%
amarin corporation plc - american depositary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/2
05:31 pm
amrn
Form 10-K AMARIN CORP PLC\UK For: Dec 31
Low
Report
Form 10-K AMARIN CORP PLC\UK For: Dec 31
2/25
07:05 am
amrn
Form 8-K AMARIN CORP PLC\UK For: Feb 25
Medium
Report
Form 8-K AMARIN CORP PLC\UK For: Feb 25
2/3
07:00 pm
amrn
Form 4 AMARIN CORP PLC\UK For: Jan 31 Filed by: Fishman Peter L.
Low
Report
Form 4 AMARIN CORP PLC\UK For: Jan 31 Filed by: Fishman Peter L.
2/3
07:00 pm
amrn
Form 4 AMARIN CORP PLC\UK For: Jan 31 Filed by: Keenan David Paul
Low
Report
Form 4 AMARIN CORP PLC\UK For: Jan 31 Filed by: Keenan David Paul
2/3
07:00 pm
amrn
Form 4 AMARIN CORP PLC\UK For: Feb 01 Filed by: Provoost Jonathan
Low
Report
Form 4 AMARIN CORP PLC\UK For: Feb 01 Filed by: Provoost Jonathan
2/3
07:00 pm
amrn
Form 4 AMARIN CORP PLC\UK For: Jan 31 Filed by: Berg Aaron
Low
Report
Form 4 AMARIN CORP PLC\UK For: Jan 31 Filed by: Berg Aaron
2/3
07:00 pm
amrn
Form 4 AMARIN CORP PLC\UK For: Jan 31 Filed by: Ketchum Steven B
Low
Report
Form 4 AMARIN CORP PLC\UK For: Jan 31 Filed by: Ketchum Steven B
1/8
07:05 am
amrn
Form 8-K AMARIN CORP PLC\UK For: Jan 08
High
Report
Form 8-K AMARIN CORP PLC\UK For: Jan 08
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/1
Amarin Co. plc (NASDAQ: AMRN) had its price target lowered by analysts at Citigroup Inc from $24.00 to $6.00. They now have a "buy" rating on the stock.
25.4%
7/2 Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance 16.3%
3/13 Amarin Co. plc (NASDAQ: AMRN) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 15.2%
4/8 2iQ Global Insider Data Helps Quants Navigate the COVID-19 Crisis 11.9%
11/14 Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsules Label Expansion to Reduce Cardiovascular Risk Based on Landmark REDUCE-IT® Outcomes Trial 11.5%
3/2 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Cowen Inc. They set an "outperform" rating and a $23.00 price target on the stock. 10.7%
8/21 Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference 9.9%
10/9 Form 4 AMARIN CORP PLC\UK For: Oct 07 Filed by: Berg Aaron 7.6%
11/12 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. 5.5%
8/9 Form 8-K AMARIN CORP PLC\UK For: Aug 08 4.7%
7/2 Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance 16.3%
3/13 Amarin Co. plc (NASDAQ: AMRN) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 15.2%
4/8 2iQ Global Insider Data Helps Quants Navigate the COVID-19 Crisis 11.9%
11/14 Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsules Label Expansion to Reduce Cardiovascular Risk Based on Landmark REDUCE-IT® Outcomes Trial 11.5%
3/2 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Cowen Inc. They set an "outperform" rating and a $23.00 price target on the stock. 10.7%
8/21 Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference 9.9%
10/9 Form 4 AMARIN CORP PLC\UK For: Oct 07 Filed by: Berg Aaron 7.6%
11/12 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. 5.5%
8/9 Form 8-K AMARIN CORP PLC\UK For: Aug 08 4.7%
TOP News Decliners
3/15
Amarin Takes Proactive Steps to Support Public Health Priorities
-17.6%
12/14 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Leerink Swann. They now have a $29.00 price target on the stock. -14.3%
4/30 Form 10-Q AMARIN CORP PLC\UK For: Mar 31 -13.3%
3/31 Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiology’s Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC) -12.3%
8/8 Amarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascepa® REDUCE-IT™ sNDA -11.3%
2/26 Form S-3ASR AMARIN CORP PLC\UK -9.6%
3/20 Amarin: Debating The Risk/Reward At These Prices [Seeking Alpha] -9.6%
2/25 Form 10-K AMARIN CORP PLC\UK For: Dec 31 -9.5%
4/2 Form 4 AMARIN CORP PLC\UK For: Mar 31 Filed by: Kennedy Joseph T -8.7%
11/19 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "underperform" rating and a $7.00 price target on the stock. -7.2%
12/14 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Leerink Swann. They now have a $29.00 price target on the stock. -14.3%
4/30 Form 10-Q AMARIN CORP PLC\UK For: Mar 31 -13.3%
3/31 Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiology’s Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC) -12.3%
8/8 Amarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascepa® REDUCE-IT™ sNDA -11.3%
2/26 Form S-3ASR AMARIN CORP PLC\UK -9.6%
3/20 Amarin: Debating The Risk/Reward At These Prices [Seeking Alpha] -9.6%
2/25 Form 10-K AMARIN CORP PLC\UK For: Dec 31 -9.5%
4/2 Form 4 AMARIN CORP PLC\UK For: Mar 31 Filed by: Kennedy Joseph T -8.7%
11/19 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "underperform" rating and a $7.00 price target on the stock. -7.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: